Cargando…

A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients

Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can...

Descripción completa

Detalles Bibliográficos
Autores principales: Vereecken, Pierre, Cornelis, Frank, Van Baren, Nicolas, Vandersleyen, Valérie, Baurain, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263591/
https://www.ncbi.nlm.nih.gov/pubmed/22287956
http://dx.doi.org/10.1155/2012/260643
_version_ 1782221890816835584
author Vereecken, Pierre
Cornelis, Frank
Van Baren, Nicolas
Vandersleyen, Valérie
Baurain, Jean-François
author_facet Vereecken, Pierre
Cornelis, Frank
Van Baren, Nicolas
Vandersleyen, Valérie
Baurain, Jean-François
author_sort Vereecken, Pierre
collection PubMed
description Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body fluids such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum biomarkers of melanoma progression and metastatic disease are still awaited in order to provide efficient rationale for followup and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma patients. However, the poor sensitivity and specificity of those markers and many other molecules are serious limitations for their routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology and proteomic research will surely provide new candidates in the near future allowing more accurate definition of the individual prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies.
format Online
Article
Text
id pubmed-3263591
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32635912012-01-27 A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients Vereecken, Pierre Cornelis, Frank Van Baren, Nicolas Vandersleyen, Valérie Baurain, Jean-François Dermatol Res Pract Review Article Many serum biomarkers have been evaluated in melanoma but their clinical significance remains a matter of debate. In this paper, a review of the serum biomarkers for melanoma will be detailed and will be discussed from the point of view of their practical usefulness. The expression of biomarkers can be detected intracellularly or on the cell membrane of melanoma cells or noncancer cells in association with the melanoma. Some of these molecules can then be released extracellularly and be found in body fluids such as the serum. Actually, with the emergence of new targeted therapies for cancer and the increasing range of therapeutic options, the challenge for the clinician is to assess the unique risk/response ratio and the prognosis for each patient. New serum biomarkers of melanoma progression and metastatic disease are still awaited in order to provide efficient rationale for followup and treatment choices. LDH as well as S100B levels have been correlated with poor prognosis in AJCC stage III/IV melanoma patients. However, the poor sensitivity and specificity of those markers and many other molecules are serious limitations for their routine use in both early (AJCC stage I and II) and advanced stages of melanoma (AJCC stage III and IV). Microarray technology and proteomic research will surely provide new candidates in the near future allowing more accurate definition of the individual prognosis and prediction of the therapeutic outcome and select patients for early adjuvant strategies. Hindawi Publishing Corporation 2012 2012-01-12 /pmc/articles/PMC3263591/ /pubmed/22287956 http://dx.doi.org/10.1155/2012/260643 Text en Copyright © 2012 Pierre Vereecken et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Vereecken, Pierre
Cornelis, Frank
Van Baren, Nicolas
Vandersleyen, Valérie
Baurain, Jean-François
A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title_full A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title_fullStr A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title_full_unstemmed A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title_short A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
title_sort synopsis of serum biomarkers in cutaneous melanoma patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263591/
https://www.ncbi.nlm.nih.gov/pubmed/22287956
http://dx.doi.org/10.1155/2012/260643
work_keys_str_mv AT vereeckenpierre asynopsisofserumbiomarkersincutaneousmelanomapatients
AT cornelisfrank asynopsisofserumbiomarkersincutaneousmelanomapatients
AT vanbarennicolas asynopsisofserumbiomarkersincutaneousmelanomapatients
AT vandersleyenvalerie asynopsisofserumbiomarkersincutaneousmelanomapatients
AT baurainjeanfrancois asynopsisofserumbiomarkersincutaneousmelanomapatients
AT vereeckenpierre synopsisofserumbiomarkersincutaneousmelanomapatients
AT cornelisfrank synopsisofserumbiomarkersincutaneousmelanomapatients
AT vanbarennicolas synopsisofserumbiomarkersincutaneousmelanomapatients
AT vandersleyenvalerie synopsisofserumbiomarkersincutaneousmelanomapatients
AT baurainjeanfrancois synopsisofserumbiomarkersincutaneousmelanomapatients